Investor mix
2 investors on record; lead investors include Vienna Insurance Group.
| Investor type | Count | Share |
|---|---|---|
| Private equity | 1 | 50% |
| Other / undisclosed | 1 | 50% |
Developer of tumour targeting antibodies and small molecule immunotherapeutics for the treatment of cancer
2 investors on record; lead investors include Vienna Insurance Group.
| Investor type | Count | Share |
|---|---|---|
| Private equity | 1 | 50% |
| Other / undisclosed | 1 | 50% |